[China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a  preclinical KAT6 inhibitor ISM5043 (MEN2312) 

Announced Date: 2024-01-04 (January 4, 2024)

Asset Name: ISM5043 (MEN2312) 

Licensor: InSilico Medicine (China)

Licensee (Buyer): Stemline Therapeutics, a subsidiary of the Menarini Group（Italy）

.

Asset Modality: Small  Molecule

Asset Target: KAT6 inhibitor

Potential Indication: hormone sensitive breast tumors and other cancers

Current Stage: preclinical

.

Scope of Authority:

Menarini Group will be granted global rights to develop and commercialize the asset. 

.

Deal Detail:

Upfront payment of  $12 million,

Development, regulatory, and commercial milestone payments, total up to $500 million.

Royalties up to double digits.

.

Link:

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

.

Note:

Chinese Name of Insilico Medicine  英矽智能